ArticleJournal of virology2019
Epidemiological Evidence for Lineage-Specific Differences in the Risk of Inapparent Chikungunya Virus Infection.
Article in Journal of virology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 2 syntheses or guidelines pooled it, 68 citations in OpenAlex.
- Clinical outcomes of chikungunya across age groups: A systematic review.PLoS neglected tropical diseases · 2025Pooled it
- The global epidemiology of chikungunya from 1999 to 2020: A systematic literature review to inform the development and introduction of vaccines.PLoS neglected tropical diseases · 2022Pooled it
- Circulation of chikungunya virus East/Central/South African lineage in Rio de Janeiro, Brazil.PloS one · 2019Trial
- Chikungunya virus: global epidemiology, transmission dynamics, and emerging challenges for public health.Infection · 2026Review
- Research advances in chikungunya virus: Epidemiology, pathogenesis, and control.One health (Amsterdam, Netherlands) · 2026Review
- Overview of Chikungunya Virus Pathogenesis, Genome Variation, Epidemiology, and Control.Virus research · 2026Review
- Article
- Age-specific chikungunya outbreak response immunisation strategies in Brazil: a modelling study.EClinicalMedicine · 2025Article
- Predictability of infectious disease outbreak severity: Chikungunya as a case study.Science advances · 2025Article
- Global, regional and national burden of chikungunya: force of infection mapping and spatial modelling study.BMJ global health · 2025Article
- Global burden of chikungunya virus infections and the potential benefit of vaccination campaigns.Nature medicine · 2025Article
- High-resolution spatiotemporal analysis of chikungunya epidemics between 2019 and 2020 in Salvador, Brazil: a municipality-level transmission dynamics study.Lancet regional health. Americas · 2025Article
- Proceedings from the Fourth Mesoamerican Symposium "Dr. Roberto Navarro López" on Emerging Zoonotic Disease and Arboviruses: Commenting Insights and Research Findings.Research and reports in tropical medicine · 2025Article
- Pathogenicity and virulence of chikungunya virus.Virulence · 2024Review
- Pathogenicity and virulence of chikungunya virus.Virulence · 2024Review
- Perinatal and Neonatal Chikungunya Virus Transmission: A Case Series.Journal of the Pediatric Infectious Diseases Society · 2024Article
- Article
- Vaccine value profile for Chikungunya.Vaccine · 2024Article
- Cryptic circulation of chikungunya virus in São Jose do Rio Preto, Brazil, 2015-2019.PLoS neglected tropical diseases · 2024Article
- Chikungunya virus antepartum transmission and abnormal infant outcomes in a cohort of pregnant women in Nigeria.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 2 countries.
Funding
Abstract
In late 2013, chikungunya virus (CHIKV) was introduced into the Americas, leading to widespread epidemics. A large epidemic caused by the Asian chikungunya virus (CHIKV) lineage occurred in Managua, Nicaragua, in 2015. Literature reviews commonly state that the proportion of inapparent CHIKV infections ranges from 3 to 28%. This study estimates the ratio of symptomatic to asymptomatic CHIKV infections and identifies risk factors of infection. In October to November 2015, 60 symptomatic CHIKV-infected children were enrolled as index cases and prospectively monitored, alongside 236 household contacts, in an index cluster study. Samples were collected upon enrollment and on day 14 or 35 and tested by real-time reverse transcription-PCR (rRT-PCR), IgM capture enzyme-linked immunosorbent assays (IgM-ELISAs), and inhibition ELISAs to detect pre- and postenrollment CHIKV infections. Of 236 household contacts, 55 (23%) had experienced previous or very recent infections, 41 (17%) had active infections at enrollment, and 21 (9%) experienced incident infections. Vehicle ownership (multivariable-adjusted risk ratio [aRR], 1.58) increased the risk of CHIKV infection, whereas ≥4 municipal trash collections/week (aRR, 0.38) and having externally piped water (aRR, 0.52) protected against CHIKV infection. Among 63 active and incident infections, 31 (49% [95% confidence interval {CI}, 36%, 62%]) were asymptomatic, yielding a ratio of symptomatic to asymptomatic infections of 1:0.97 (95% CI, 1:0.56, 1:1.60). Although our estimate is outside the 3% to 28% range reported previously, Bayesian and simulation analyses, informed by a systematic literature search, suggested that the proportion of inapparent CHIKV infections is lineage dependent and that more inapparent infections are associated with the Asian lineage than the East/Central/South African (ECSA) lineage. Overall, these data substantially improve knowledge regarding chikungunya epidemics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.